Prevalence of Elevated Lipoprotein(a) and its Association With Subclinical Atherosclerosis in 2.9 Million Chinese Adults (2025)

1. Berg K. "A new serum type system in man—the Lp system". Acta Pathol Microbiol Scand . 1963;59:369-382.

2. Patel A.P., Wang M., Pirruccello J.P., et al. "Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national Biobank". Arterioscler Thromb Vasc Biol . 2021;41:1: 465-474.

3. Erqou S., Kaptoge S., Perry P.L., et al.Emerging Risk Factors Collaboration. "Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality". JAMA . 2009;302:4: 412-423.

4. Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., Nordestgaard B.G. "Genetically elevated lipoprotein(a) and increased risk of myocardial infarction". JAMA . 2009;301:22: 2331-2339.

5. Clarke R., Peden J.F., Hopewell J.C., et al. "Genetic variants associated with Lp(a) lipoprotein level and coronary disease". N Engl J Med . 2009;361:26: 2518-2528.

6. Varvel S., McConnell J.P., Tsimikas S. "Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States". Arterioscler Thromb Vasc Biol . 2016;36:11: 2239-2245.

7. Duarte Lau F., Giugliano R.P. "Lipoprotein(a) and its significance in cardiovascular disease: a review". JAMA Cardiol . 2022;7:7: 760-769.

8. Libby P., Buring J.E., Badimon L., et al. "Atherosclerosis". Nat Rev Dis Primers . 2019;5:1: 56.

9. Willeit P., Tschiderer L., Allara E., et al. "Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100 667 patients". Circulation . 2020;142:7: 621-642.

10. Khan S.S., Post W.S., Guo X., et al. "Coronary artery calcium score and polygenic risk score for the prediction of coronary heart disease events". JAMA . 2023;329:20: 1768-1777.

11. Steffen B.T., Thanassoulis G., Duprez D., et al. "Race-based differences in lipoprotein(a)-associated risk of carotid atherosclerosis". Arterioscler Thromb Vasc Biol . 2019;39:3: 523-529.

12. Lin L., Deng K.Q., Chen Z., et al. "Lipoprotein(a) distribution and its association with carotid arteriopathy in the Chinese population". Atherosclerosis . 2023;372:1-9.

13. Duan Y., Zhao D., Sun J., et al. "Lipoprotein(a) is associated with the progression and vulnerability of new-onset carotid atherosclerotic plaque". Stroke . 2023;54:5: 1312-1319.

14. Martignoni F.V., Rl Junior J.E., Marques I.R., et al. "The association of lipoprotein(a) and coronary artery calcium in asymptomatic patients: a systematic review and meta-analysis". Eur J Prev Cardiol . 2024;31:6: 732-741.

15. Jackson C.L., Garg P.K., Guan W., et al. "Lipoprotein(a) and coronary artery calcium in comparison with other lipid biomarkers: the Multi-Ethnic Study of Atherosclerosis". J Clin Lipidol . 2023;17:4: 538-548.

16. China Health Culture Association-Medical and Health Credit Branch, China Cheng Xin International Credit Rating Co, Frost and Sullivan. "White paper: insight into trends in China's Health Management Services Industries China". 2021. Accessed March 6, 2025. http://www.ccx.com.cn/uploads/files/2022/0419/uybiaAKocvizUWkyJ12KnNtabX3zGvyqTxzx5rvo.pdf.

17. Man S., Deng Y., Ma Y., et al. "Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China". Gastroenterology . 2023;165:4: 1025-1040.

18. Kronenberg F., Mora S., Stroes E.S.G., et al. "Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement". Eur Heart J . 2022;43:39: 3925-3946.

19. Reyes-Soffer G., Ginsberg H.N., Berglund L., et al. "Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association". Arterioscler Thromb Vasc Biol . 2022;42:1: e48-e60.

20. Li J.J., Ma C.S., Zhao D., Yan X.W., Beijing Heart Society and Expert Committee. "Lipoprotein(a) and cardiovascular disease in Chinese population: A Beijing Heart Society expert scientific statement". JACC Asia . 2022;2:6: 653-665.

21. Koschinsky M.L., Bajaj A., Boffa M.B., et al. "A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice". J Clin Lipidol . 2024;18:3: e308-e319.

22. Zhu X., Cheng X., Zhong Y. "Establishment of reference interval of particle concentration for detecting lipoprotein(a) in Beijing". Lin Chuang Jian Yan Za Zhi . 2022;40:3: 204-208.

23. Malick W.A., Goonewardena S.N., Koenig W., Rosenson R.S. "Clinical trial design for lipoprotein(a)-lowering therapies: JACC focus seminar 2/3". J Am Coll Cardiol . 2023;81:16: 1633-1645.

24. Stein J.H., Korcarz C.E., Hurst R.T., et al. "Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine". J Am Soc Echocardiogr . 2008;21:2: 93-111.quiz 89-90.

25. Wang X., Zhang R., Man S., et al. "Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis". Liver Int . 2023;43:8: 1691-1698.

26. Chauhan G., Adams H.H.H., Satizabal C.L., et al. "Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting". Neurology . 2019;92:5: e486-e503.

27. Xu J., Liu J., Guo N., et al. "Performance of artificial intelligence-based coronary artery calcium scoring in non-gated chest CT". Eur J Radiol . 2021;145:110034.

28. Rumberger J.A., Brundage B.H., Rader D.J., Kondos G. "Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons". Mayo Clin Proc . 1999;74:3: 243-252.

29. Xia J., Guo C., Cao H., et al. "Impact of lipoprotein(a) level on cardiometabolic disease in the Chinese population: the CHCN-BTH Study". Eur J Clin Invest . 2022;52:2: e13689.

30. Vaverkova H., Karasek D., Halenka M., Cibickova L., Kubickova V. "Inverse association of lipoprotein (a) with markers of insulin resistance in dyslipidemic subjects". Physiol Res . 2017;66:Suppl 1: S113-S120.

31. Jung I., Kwon H., Park S.E., et al. "Serum lipoprotein(a) levels and insulin resistance have opposite effects on fatty liver disease". Atherosclerosis . 2020;308:1-5.

32. Reyes-Soffer G., Westerterp M. "Beyond lipoprotein(a) plasma measurements: lipoprotein(a) and inflammation". Pharmacol Res . 2021;169:105689.

33. Ritter M.M., Geiss H.C., Richter W.O., Schwandt P. "Lipoprotein(a) concentrations and phenotypes in controls and patients with hypercholesterolemia or hypertriglyceridemia". Metabolism . 1994;43:5: 572-578.

34. Larsson S.C., Wang L., Li X., Jiang F., Chen X., Mantzoros C.S. "Circulating lipoprotein(a) levels and health outcomes: Phenome-wide Mendelian randomization and disease-trajectory analyses". Metabolism . 2022;137:155347.

35. Randall O.S., Feseha H.B., Illoh K., et al. "Response of lipoprotein(a) levels to therapeutic life-style change in obese African-Americans". Atherosclerosis . 2004;172:1: 155-160.

36. Schmidt H., Wagner S., Kolm R., Manns M. "Lipoprotein(a) in cirrhosis". BMJ . 1992;304:6835: 1180.

37. Kronenberg F., Kuen E., Ritz E., et al. "Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure". J Am Soc Nephrol . 2000;11:1: 105-115.

38. Kronenberg F., Konig P., Neyer U., et al. "Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis". J Am Soc Nephrol . 1995;6:1: 110-120.

39. Fernandez-Friera L., Penalvo J.L., Fernandez-Ortiz A., et al. "Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: the PESA (Progression of Early Subclinical Atherosclerosis) Study". Circulation . 2015;131:24: 2104-2113.

40. Peng J., Liu M.M., Liu H.H., et al. "Lipoprotein (a)-mediated vascular calcification: population-based and in vitro studies". Metabolism . 2022;127:154960.

41. Guerra R., Yu Z., Marcovina S., Peshock R., Cohen J.C., Hobbs H.H. "Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study". Circulation . 2005;111:12: 1471-1479.

42. Guan W., Cao J., Steffen B.T., et al. "Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis". Arterioscler Thromb Vasc Biol . 2015;35:4: 996-1001.

43. Wang L., Zhou B., Zhao Z., et al. "Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004-18". Lancet . 2021;398:10294: 53-63.

44. Zhang M., Shi Y., Zhou B., et al. "Prevalence, awareness, treatment, and control of hypertension in China, 2004-18: findings from six rounds of a national survey". BMJ . 2023;380:e071952.

45. Yang W., Lu J., Weng J., et al. "Prevalence of diabetes among men and women in China". N Engl J Med . 2010;362:12: 1090-1101.

46. Lu Y., Zhang H., Lu J., et al. "Prevalence of dyslipidemia and availability of lipid-lowering medications among primary health care settings in China". JAMA Netw Open . 2021;4:9: e2127573.